TY - T1的额颞叶障碍的发生率和趋势在奥姆斯特德县:基于人口的研究(1995 - 2010)。(p2.1 - 001) JF 首页-神经学乔-神经学六世- 92 - 15补充SP - p2.1 - 001 AU -又是Turcano AU -科尔刺伤AU -米歇尔Mielke盟-亚历山德拉Wennberg AU -基思·约瑟夫盟- j . Ahlskog AU -布拉德利Boeve AU - David Knopman AU -罗纳德·彼得森盟Rodolfo Savica Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p2.1 - 001. -文摘N2 -目的:探讨额颞叶痴呆疾病的发病率(ftd)以人群为基础的队列。背景:ftd异构表型综合症,表现为行为和语言障碍通常与额叶或颞叶退化。设计/方法:使用records-linkage系统的罗彻斯特流行病学项目中,我们发现所有患者筛查诊断代码痴呆奥姆斯特德县MN从1995年到2010年。我们使用自然语言处理软件确认ftd诊断的存在。行为神经学家证实了临床诊断和确定的临床表型。结果:我们发现35 ftd例:22(62.9%)是男性。平均诊断年龄是70岁(范围:48 - 94)。平均随访时间为3年(范围:1 12月年)。17/35(48.6%)的行为FTD变体;1有一个混合的临床诊断(行为变异+语义变体FTD);1有流利的原发性进行性失语(PPA); 1 non-fluent PPA; 1 PPA NOS; 1 had FTD with motor neuron disease; and 13/35 (37.1%) were unspecified. 10/35 (28.6%) reported depression within 5 years preceding the clinical diagnosis. 13/35 (37.1%) patients had at least one MRI before their diagnosis (range: 3 days–6 years); all presented with cortical atrophy consistent with the clinical diagnosis. 6/35 (17.1%) patients underwent PET or SPECT examination before the clinical diagnosis (range: 1 month–19 months), all showing hypometabolism of the frontal, temporal and/or parietal lobes. At autopsy, clinical diagnosis was confirmed in 6/11 (54.5%) cases. Overall FTDs incidence was 4.3/100,000 per year (95% CI 2.9, 5.7, P<0.001). Incidence was higher in men (6.3/100,000, 95% CI 3.6, 9.0, P<0.001) than women (2.9/100,000; 95% CI 1.3, 4.5, P<0.001). Incidence trended upwards over time (B= 0.83, 95% CI 0.54, 1.11, P<0.001).Conclusions: We observed an increased incidence of FTDs over time. This may reflect a better recognition by clinicians, and improvement of clinical criteria and diagnostic tools.Disclosure: Dr. Turcano has nothing to disclose. Dr. Stang has nothing to disclose. Dr. Mielke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Lysosomal Therapeutics, Inc. Dr. Mielke has received research support from Biogen, Roche, and Lundbeck. Dr. Wennberg has nothing to disclose. Dr. Josephs has nothing to disclose. Dr. Ahlskog has nothing to disclose. Dr. Boeve has received research support from Biogen. Dr. Knopman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Washington University for the DIAN study. Dr. Knopman has received research support from Biogen Pharmaceuticals and Lilly Pharmaceuticals. Dr. Petersen has nothing to disclose. Dr. Savica has nothing to disclose. ER -